Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Proactively manage your pharmacy inventory
Find generic entry opportunities
Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
|Title:||Oral liquid alendronate formulations|
|Abstract:||Disclosed is a therapy protocol for treating and for preventing bone loss in patients who have difficulty in swallowing by administering a liquid formulation of alendronate which can be easily swallowed. Also described are pharmaceutical dosage forms of a syrup, aqueous solution, a solution formed from a reconstituted powder, of alendronate, for carrying out the therapeutic method.|
|Inventor(s):||Brenner; Gerald S. (Norristown, PA), Katdare; Ashok V. (Norristown, PA), Pretzer; Denise (Chesterfield, MO), Whiteford; Donna T. (Brooklyn, NY)|
|Assignee:||Merck & Co., Inc. (Rahway, NJ)|
Patent Claim Types:|
see list of patent claims
|Use; Composition; Formulation; Compound;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.